Researchers are edging closer to something long imagined but never quite within reach: a single vaccine platform that could ...

Sean Ryder, professor at UMass Chan Medical School, has written a book to delve the mysteries of ribonucleic acid as a tool to fight diseases. Messenger ribonucleic acid, or mRNA, is in the public ...

Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and ...

A Stanford-led study probes why a very small number of people develop heart inflammation shortly after mRNA COVID-19 ...

Researchers at MIT have unveiled a way to temporarily reboot aging immune systems, using a targeted mRNA therapy that turns ...

The era of CureVac as an independent, publicly traded company has drawn to a close. BioNTech SE has successfully completed ...

As the immune system weakens with age, researchers have found a way to temporarily boost its function by reprogramming liver cells to support T-cell development.

The independent journey of CureVac as a publicly traded company has reached its conclusion. Following the expiration of the acceptance period, BioNTech has s ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...